Table 3.
BOD vs EOC | Marker | ROC-AUC (95 % CI) | Cutoff optimal/preferred | Sensitivity (%) optimal/preferred | Specificity (%) optimal/preferred | PPV (%) optimal/preferred | NPV (%) optimal/preferred |
---|---|---|---|---|---|---|---|
all | HE4 | 0.895 (0.838–0.951) | 72.3 / 140 (pmol/l) | 84.1 / 67.1 | 86.3 / 97.5 | 45.2 / 87.4 | 97.6 / 92.1 |
CA125 | 0.879 (0.818–0.941) | 62.2 / 35 (U/ml) | 83.1 / 81.9 | 82.4 / 74.1 | 41.6 / 36.9 | 93.9 / 96.2 | |
ROMA | 0.918 (0.853–0.938) | 20.1 / 11.4; 29.9 (%) | 86.2 / 84.8 | 86.8 / 88.2 | 39.4 / 36.3 | 94.4 / 96.6 | |
pre-menopausal | HE4 | 0.845 (0.806–0.894) | 70.3 / 140 (pmol/l) | 83.5 / 68.2 | 89.8 / 98.6 | 46.2 / 86.4 | 96.7 / 94.4 |
CA125 | 0.833 (0.753–0.944) | 64.6 / 35 (U/ml) | 87.0 / 86.6 | 84.1 / 70.9 | 44.8 / 33.6 | 94.8 / 96.1 | |
ROMA | 0.854 (0.778–0.876) | 14.9 / 11.4 (%) | 86.8 / 86.2 | 89.1 / 88.8 | 42.1 / 39.6 | 97.2 / 98.7 | |
post-menopausal | HE4 | 0.916 (0.841–0.979) | 109.1 / 140 (pmol/l) | 83.8 / 87.1 | 96.9 / 94.2 | 86.8 / 92.8 | 89.6 / 86.2 |
CA125 | 0.904 (0.855–0.943) | 39.4 / 35 (U/ml) | 84.1 / 91.9 | 96.7 / 89.8 | 91.7 / 83.2 | 92.8 / 94.4 | |
ROMA | 0.931 (0.898–0.959) | 33.4 / 29.9 (%) | 89.0 / 86.8 | 95.9 / 92.2 | 91.9 / 89.4 | 94.2 / 94.9 |
BOD benign ovarian diseases, EOC epithelial ovarian cancer